SRR1313114
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.480
- OXIDATIVE_PHOSPHORYLATION+0.420
- CHOLESTEROL_HOMEOSTASIS+0.330
- UV_RESPONSE_UP+0.290
- INTERFERON_GAMMA_RESPONSE+0.280
- ADIPOGENESIS+0.260
- FATTY_ACID_METABOLISM+0.260
- COAGULATION+0.230
- PANCREAS_BETA_CELLS+0.230
- MTORC1_SIGNALING+0.220
Top 10 suppressed
- MITOTIC_SPINDLE-0.260
- NOTCH_SIGNALING-0.260
- WNT_BETA_CATENIN_SIGNALING-0.250
- ALLOGRAFT_REJECTION-0.220
- KRAS_SIGNALING_UP-0.220
- UV_RESPONSE_DN-0.190
- IL6_JAK_STAT3_SIGNALING-0.180
- IL2_STAT5_SIGNALING-0.160
- HEDGEHOG_SIGNALING-0.120
- HYPOXIA-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_AVYNZHSB | subependymal giant cell astrocytoma(SEGA) | — | 0.763 |
| 2 | BS_EYYMKWB7 | subependymal giant cell astrocytoma(SEGA) | — | 0.724 |
| 3 | 713c3ad2-c1d0-45ed-b69e-f6cedd57933a | — | — | 0.723 |
| 4 | TCGA-B6-A0RH-01A-21R-A115-07 | — | B | 0.702 |
| 5 | TCGA-E9-A1NI-01A-11R-A14D-07 | — | C | 0.701 |
| 6 | MNG785 | — | — | 0.698 |
| 7 | TCGA-A8-A07Z-01A-11R-A00Z-07 | — | B | 0.694 |
| 8 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.693 |
| 9 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.692 |
| 10 | TCGA-A8-A08J-01A-11R-A00Z-07 | — | B | 0.692 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |